Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00210392
Status:
TERMINATED
Last Update Posted:
2015-03-30
First Post:
2005-09-13
Brief Title:
VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy
Sponsor:
International Extranodal Lymphoma Study Group IELSG
Organization:
International Extranodal Lymphoma Study Group IELSG
Study Overview
Official Title:
Phase II Study of VELCADE in Patients With Extranodal Marginal Zone B-Cell Lymphoma of MALT-Type Pretreated With More Than One Prior Systemic Therapy Regimen X05142
Status:
TERMINATED
Status Verified Date:
2015-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
After IELSG25A study amendment patients subject of the present study were eligible for inclusion in the IELSG25A study
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to assess the antitumor activity in terms of overall response rate - ORR - ie sum of complete and partial responses of bortezomib in pretreated MALT lymphomas with more than one prior systemic therapy regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None